CN1784242B - 通过小核糖核酸病毒直接介导的溶瘤作用治疗受试者恶性肿瘤的方法 - Google Patents

通过小核糖核酸病毒直接介导的溶瘤作用治疗受试者恶性肿瘤的方法 Download PDF

Info

Publication number
CN1784242B
CN1784242B CN2003801098083A CN200380109808A CN1784242B CN 1784242 B CN1784242 B CN 1784242B CN 2003801098083 A CN2003801098083 A CN 2003801098083A CN 200380109808 A CN200380109808 A CN 200380109808A CN 1784242 B CN1784242 B CN 1784242B
Authority
CN
China
Prior art keywords
cells
virus
cell
ovarian cancer
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2003801098083A
Other languages
English (en)
Chinese (zh)
Other versions
CN1784242A (zh
Inventor
D·雪弗伦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Virotago Private Ltd
Viralytics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virotago Private Ltd, Viralytics Ltd filed Critical Virotago Private Ltd
Publication of CN1784242A publication Critical patent/CN1784242A/zh
Application granted granted Critical
Publication of CN1784242B publication Critical patent/CN1784242B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32311—Enterovirus
    • C12N2770/32332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN2003801098083A 2002-12-18 2003-12-18 通过小核糖核酸病毒直接介导的溶瘤作用治疗受试者恶性肿瘤的方法 Expired - Fee Related CN1784242B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2002953436A AU2002953436A0 (en) 2002-12-18 2002-12-18 A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
AU2002953436 2002-12-18
PCT/AU2003/001688 WO2004054613A1 (en) 2002-12-18 2003-12-18 A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201110091011.1A Division CN102166228B (zh) 2002-12-18 2003-12-18 通过小核糖核酸病毒直接介导的溶瘤作用治疗受试者恶性肿瘤的方法

Publications (2)

Publication Number Publication Date
CN1784242A CN1784242A (zh) 2006-06-07
CN1784242B true CN1784242B (zh) 2011-06-08

Family

ID=30004521

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2003801098083A Expired - Fee Related CN1784242B (zh) 2002-12-18 2003-12-18 通过小核糖核酸病毒直接介导的溶瘤作用治疗受试者恶性肿瘤的方法
CN201110091011.1A Expired - Fee Related CN102166228B (zh) 2002-12-18 2003-12-18 通过小核糖核酸病毒直接介导的溶瘤作用治疗受试者恶性肿瘤的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201110091011.1A Expired - Fee Related CN102166228B (zh) 2002-12-18 2003-12-18 通过小核糖核酸病毒直接介导的溶瘤作用治疗受试者恶性肿瘤的方法

Country Status (11)

Country Link
US (2) US7485292B2 (https=)
EP (1) EP1581257B1 (https=)
JP (2) JP2006517189A (https=)
KR (1) KR101171295B1 (https=)
CN (2) CN1784242B (https=)
AU (1) AU2002953436A0 (https=)
CA (1) CA2510227C (https=)
ES (1) ES2463678T3 (https=)
NZ (1) NZ541230A (https=)
WO (1) WO2004054613A1 (https=)
ZA (1) ZA200505389B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
AU2002953436A0 (en) * 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
KR101295733B1 (ko) 2004-08-20 2013-08-13 비랄리틱스 리미티드 혈액암의 치료방법 및 조성물
EP1843773A4 (en) * 2005-01-17 2008-07-30 Viralytics Ltd METHOD AND COMPOSITION FOR TREATING NEOPLASIA
WO2013157648A1 (ja) 2012-04-19 2013-10-24 国立大学法人九州大学 医薬組成物
PL2826856T3 (pl) * 2013-07-16 2016-06-30 Sia Latima Genetycznie stabilny onkolityczny wirus RNA, sposób jego wytwarzania i zastosowanie
WO2015080631A1 (en) * 2013-11-27 2015-06-04 Obschestvo S Ogranichennoy Otvetstvennost`Yu "Panacela Labs" Improved expression vector for toll-like receptor and agonist and use for treating cancer
EP3110443A4 (en) 2014-02-27 2017-11-15 Viralytics Limited Combination method for treatment of cancer
CN103981152B (zh) * 2014-04-16 2015-01-21 武汉博威德生物技术有限公司 一种柯萨奇病毒及其制备抗肿瘤药物之应用
JP7138946B2 (ja) 2016-09-27 2022-09-20 セイター セラピューティクス エルエルシー 最適化された腫瘍溶解性ウイルスおよびその使用
EP3610870A4 (en) 2017-03-31 2020-12-09 Ogata, Hisanobu METHOD OF EXPANSION OF AN ONCOLYTIC VIRUS AND ANTI-TUMOR AGENT
CN109419818B (zh) * 2017-08-24 2021-08-10 厦门大学 一种用于治疗肿瘤的埃可病毒
CN107669707A (zh) * 2017-11-16 2018-02-09 邹罡 埃可病毒作为溶瘤病毒在抗肿瘤中的应用
MX2021005448A (es) * 2018-11-13 2021-08-11 Oncorus Inc Polinucleotidos encapsulados y metodos de uso.
CA3207359A1 (en) 2021-02-05 2022-08-11 Cecile Chartier-Courtaud Adjuvant therapy for cancer

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54113421A (en) * 1978-02-24 1979-09-05 Fumiaki Taguchi Large scale cultivation of virus
US5585254A (en) 1987-08-21 1996-12-17 University Of Colorado Foundation, Inc. Autonomous parvovirus gene delivery vehicles and expression vectors
JPH04504361A (ja) 1989-04-05 1992-08-06 ノバセル　コーポレイション 感染性標的化複製―欠陥ビリオン
CA2051289C (en) 1990-09-14 2002-11-26 Robert L. Martuza Viral mediated destruction of neoplastic cells
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
EP0591382A4 (en) 1991-06-24 1995-01-18 Univ New York DE NOVO CELL-FREE SYNTHESIS OF PICORNAVIRUS.
CA2113990A1 (en) 1991-07-26 1993-02-18 Frederick L. Moolten Cancer therapy utilizing malignant cells
US5529774A (en) 1991-08-13 1996-06-25 The Regents Of The University Of California In vivo transfer of the HSV-TK gene implanted retroviral producer cells
SE503225C2 (sv) 1991-10-30 1996-04-22 Leif Lindholm Konsult Ab Virus-antikroppskomplex för införing av virus i mammalieceller
US5801029A (en) 1993-02-16 1998-09-01 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
ATE178490T1 (de) 1993-02-16 1999-04-15 Onyx Pharmaceuticals Cytopathische viren zur therapie und prophylaxe der neoplasie
CA2161671A1 (en) 1993-04-30 1994-11-10 Robert M. Lorence Methods of treating and detecting cancer using viruses
US5728379A (en) 1994-06-23 1998-03-17 Georgetown University Tumor- or cell-specific herpes simplex virus replication
US5585096A (en) 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
US5688773A (en) 1994-08-17 1997-11-18 The General Hospital Corporation Method of selectively destroying neoplastic cells
US6071742A (en) 1997-03-05 2000-06-06 Board Of Regents Of The University Of Nebraska Coxsackie virus as a vector for delivery of anti-inflammatory cytokines
US6136307A (en) 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
US6110461A (en) 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
CN101618049A (zh) 1997-10-09 2010-01-06 威尔斯塔特生物公司 使用病毒来治疗赘生物
EP1061806A4 (en) 1998-03-12 2001-09-12 Univ Pennsylvania REPLICATING VIRUS PRODUCING CELLS FOR TREATING MALIGNANCY
US6060316A (en) 1998-06-09 2000-05-09 President And Fellows Of Harvard College Methods of targeting of viral entry
US6264940B1 (en) 1998-08-05 2001-07-24 The Research Foundation Of State University Of New York Recombinant poliovirus for the treatment of cancer
ATE402713T1 (de) 1999-02-05 2008-08-15 Arch Dev Corp Genetisch manipulierte herpesviren zur behandlung von tumoren
IL145899A0 (en) 1999-04-15 2002-07-25 Pro Virus Inc Treatment of neoplasms with viruses
AU2005201079C1 (en) 1999-04-15 2008-11-06 Wellstat Biologics Corporation Treatment of neoplasms with viruses
EP1067188A1 (en) 1999-07-08 2001-01-10 Introgene B.V. Infection with chimaeric adenoviruses of cells negative for the adenovirus serotype 5 Coxsacki adenovirus receptor (CAR)
DE19939095A1 (de) 1999-08-18 2001-02-22 Univ Eberhard Karls Von Coxsackieviren abgeleitetes Vektorsystem für Gentransfer
IL148621A0 (en) 1999-09-17 2002-09-12 Pro Virus Inc Oncolytic virus
BR0015491A (pt) 1999-11-12 2002-10-15 Oncolytics Biotech Inc Métodos para tratar um distúrbio proliferativo celular mediado por ras em um mamìfero, para tratar um neoplasma tendo uma via-ras ativada em um humano, para inibir metástase de um neoplasma tendo uma via-ras ativada em um mamìfero, e para tratar um neoplasma suspeito de ter uma via-ras ativada em um mamìfero, composição farmacêutica, kit, e, método para tratar uma população de células compreendendo um neoplasma suspeito de ter uma via-ras ativada in vitro
CN1382218A (zh) 1999-11-15 2002-11-27 昂尼克斯药物公司 溶瘤腺病毒
AU770517B2 (en) 1999-11-25 2004-02-26 Viralytics Limited A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
AU2004202292B2 (en) 1999-11-25 2007-06-14 Viralytics Limited Method of Treating a Malignancy in a Subject
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
GB2375113B (en) 2000-01-21 2004-10-20 Biovex Ltd A modified, oncolytic, non-laboratory HSV strain and its use in treating cancer
CA2341356C (en) 2000-04-14 2011-10-11 Transgene S.A. Poxvirus with targeted infection specificity
US7306902B2 (en) 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
AU6814601A (en) 2000-06-01 2001-12-11 Sloan Kettering Inst Cancer Use of mutant herpes viruses and anticancer agents in the treatment of cancer
JP2004519431A (ja) 2000-12-01 2004-07-02 ユニバーシティ・オブ・オタワ 腫瘍溶解性ウイルス
AU2002318104A1 (en) * 2001-01-05 2002-11-25 Corixa Corporation Microparticles and methods for delivery of recombinant viral vaccines
EP1406668A1 (en) 2001-05-02 2004-04-14 Ramot at Tel-Aviv University Ltd. Composite oncolytic herpes virus vectors
EP2213300B1 (en) 2001-05-09 2015-03-25 Takara Bio, Inc. Composition and method for treating cancer using herpes virus
HUP0400882A3 (en) 2001-05-11 2011-01-28 Wellstat Biologics Corp Oncolytic virus therapy
CA2352439A1 (en) 2001-07-17 2003-01-17 Patrick W. K. Lee Engineering oncolytic viruses
WO2003010306A1 (en) 2001-07-23 2003-02-06 Onyx Pharmaceuticals, Inc. Viral mutants that selectively replicate in targeted human cancer cells
CA2476724A1 (en) 2002-03-01 2003-09-12 Sloan-Kettering Institute For Cancer Research Prevention of recurrence and metastasis of cancer
AU2003258060B2 (en) 2002-03-27 2007-07-12 Baylor College Of Medicine Potent oncolytic herpes simplex virus for cancer therapy
AU2003223089A1 (en) 2002-04-29 2003-11-17 Hadasit Medical Research Services And Development Company Ltd. Compositions and methods for treating cancer with an oncolytic viral agent
JP5241059B2 (ja) 2002-05-09 2013-07-17 オンコリティクス バイオテク，インコーポレーテッド 腫瘍崩壊ウイルスを使用して疼痛を軽減するための方法
AU2002953436A0 (en) * 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
WO2005002607A2 (en) 2003-07-07 2005-01-13 Oncolytics Biotech Inc. Oncolytic reoviruses for the treatment of neoplasms having activated pp2a or rac
WO2005007824A2 (en) 2003-07-08 2005-01-27 Arizona Board Of Regents Mutants of vaccinia virus as oncolytic agents
MXPA06003318A (es) 2003-09-26 2006-06-08 Novartis Ag Composiciones a base de virus de seneca valley y metodos para tratar la enfermedad.
US8114416B2 (en) 2004-03-11 2012-02-14 Viralytics Limited Modified oncolytic viruses
US20080292592A1 (en) 2004-04-30 2008-11-27 Sunil Chada Oncolytic Adenovirus Armed with Therapeutic Genes
WO2006002394A2 (en) 2004-06-24 2006-01-05 New York University Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
US8080240B2 (en) 2004-10-21 2011-12-20 The Penn State Research Foundation Parvovirus methods and compositions for killing neoplastic cells

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Gerasimos Anastassiou等.Expression of VLA-2,VLA-3,and αv integrin receptors inuvealmelanoma: association with microvasculararchitectureofthetumour and prognostic value.Br F Ophthalmol 84.2000,(84),899,901.
Gerasimos Anastassiou等.Expression of VLA-2,VLA-3,and αv integrin receptors inuvealmelanoma: association with microvasculararchitectureofthetumour and prognostic value.Br F Ophthalmol 84.2000,(84),899,901. *
John Nemunaitis.Oncolytic viruses.Investigational New Drugs 17.1999,(17),375-386.
John Nemunaitis.Oncolytic viruses.Investigational New Drugs 17.1999,(17),375-386. *
Martha Triantafilou等.Identification of Echovirus 1 and coxsackievirusA9receptormolecules via a novel flow cytometricquantificationmethod.Cytometry 43.2001,(43),279,287.
Martha Triantafilou等.Identification of Echovirus 1 and coxsackievirusA9receptormolecules via a novel flow cytometricquantificationmethod.Cytometry 43.2001,(43),279,287. *

Also Published As

Publication number Publication date
EP1581257A4 (en) 2007-10-17
US20060134778A1 (en) 2006-06-22
KR101171295B1 (ko) 2012-08-07
ZA200505389B (en) 2006-09-27
CA2510227C (en) 2015-03-31
EP1581257A1 (en) 2005-10-05
HK1082194A1 (en) 2006-06-02
CA2510227A1 (en) 2004-07-01
WO2004054613A1 (en) 2004-07-01
HK1157657A1 (en) 2012-07-06
CN1784242A (zh) 2006-06-07
NZ541230A (en) 2008-04-30
KR20050115859A (ko) 2005-12-08
CN102166228B (zh) 2014-02-19
CN102166228A (zh) 2011-08-31
US20100062020A1 (en) 2010-03-11
AU2002953436A0 (en) 2003-01-09
EP1581257B1 (en) 2014-04-30
US7485292B2 (en) 2009-02-03
JP2012046489A (ja) 2012-03-08
JP2006517189A (ja) 2006-07-20
ES2463678T3 (es) 2014-05-28

Similar Documents

Publication Publication Date Title
US20100062020A1 (en) Method of Treating a Malignancy in a Subject Via Direct Picornaviral-Mediated Oncolysis
Pawlik et al. Oncolysis of diffuse hepatocellular carcinoma by intravascular administration of a replication-competent, genetically engineered herpesvirus
Springfeld et al. Oncolytic efficacy and enhanced safety of measles virus activated by tumor-secreted matrix metalloproteinases
Shafren et al. Oncolysis of human ovarian cancers by echovirus type 1
Ontiveros et al. Enhanced virulence mediated by the murine coronavirus, mouse hepatitis virus strain JHM, is associated with a glycine at residue 310 of the spike glycoprotein
AU2010224426A1 (en) Modified oncolytic viruses
CN101132798B (zh) 核酸分子在制备用于治疗黑色素瘤的药物中的应用及其组合物
CN111405902B (zh) 用柯萨奇病毒b3(cvb3)变体治疗癌症的方法
AU2003287773C1 (en) A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
HK1082194B (en) Composition comprising echovirus ev1 and its use
HK1157657B (en) A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
Traube et al. 779. Genetic Delivery of an Anti-RSV Antibody Protects Against Pulmonary Infection with RSV in Mice
CN116769734A (zh) 一种缺氧微环境响应溶瘤病毒株的构建及其应用
Wollenberg Tweaking reovirus T3D to boost the oncolytic potency
Biotech LOW PATHOGENIC HUMAN ENTEROVIRUSES AS NOVEL ANTI-CANCER AGENTS AGAINST MALIGNANT GLIOMA
Volders et al. Acquisition of Macrophage Tropism during

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: RONGLIU VIRUS CO., LTD.

Free format text: FORMER OWNER: VIROTARG PTY LTD.

Effective date: 20071116

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20071116

Address after: New South Wales, Australia

Applicant after: Psiron Ltd.

Address before: New South Wales, Australia

Applicant before: Virotarg Pty Ltd.

C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20190812

Address after: new jersey

Patentee after: Schering Corporation

Address before: New South Wales, Australia

Patentee before: Psiron Ltd.

TR01 Transfer of patent right
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20110608

Termination date: 20201218